Jeff Jones
Stock Analyst at Oppenheimer
(4.69)
# 762
Out of 4,564 analysts
275
Total ratings
43.7%
Success rate
19.8%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Reiterated: Buy | $55 | $28.30 | +94.35% | 14 | Jul 15, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $40 | $17.67 | +126.37% | 2 | Jun 18, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $54 → $52 | $9.32 | +457.94% | 23 | Jun 17, 2026 | |
| ACRV Acrivon Therapeutics | Initiated Coverage: Buy | $8 | $1.67 | +379.04% | 1 | Jun 15, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $45 | $19.33 | +132.86% | 1 | Jun 15, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $2.95 | +340.68% | 31 | Jun 1, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $50 | $31.54 | +58.53% | 8 | Jun 1, 2026 | |
| MDWD MediWound | Maintained: Buy | $34 → $32 | $14.27 | +124.25% | 5 | May 28, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterated: Buy | $33 | $13.68 | +141.23% | 17 | May 15, 2026 | |
| CMMB Chemomab Therapeutics | Maintained: Buy | $25 | $1.40 | +1,685.71% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 → $66 | $28.40 | +132.39% | 8 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $1.33 | +275.94% | 16 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $33.26 | +50.33% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $5.48 | +82.48% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $3.83 | +82.77% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 → $40 | $13.17 | +203.72% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $35.51 | +142.19% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.47 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $110.38 | +8.72% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $5.29 | +202.46% | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $20 | $6.38 | +213.48% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.08 | - | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.23 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.92 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.08 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.49 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.8751 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.05 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.011 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $55.58 | n/a | 1 | Jun 22, 2021 |
Alumis
Jul 15, 2026
Reiterated: Buy
Price Target: $55
Current: $28.30
Upside: +94.35%
Odyssey Therapeutics
Jun 18, 2026
Reiterated: Buy
Price Target: $40
Current: $17.67
Upside: +126.37%
Corbus Pharmaceuticals Holdings
Jun 17, 2026
Reiterated: Buy
Price Target: $54 → $52
Current: $9.32
Upside: +457.94%
Acrivon Therapeutics
Jun 15, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.67
Upside: +379.04%
Ascentage Pharma Group International
Jun 15, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $19.33
Upside: +132.86%
Perspective Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $13
Current: $2.95
Upside: +340.68%
ArriVent BioPharma
Jun 1, 2026
Reiterated: Buy
Price Target: $50
Current: $31.54
Upside: +58.53%
MediWound
May 28, 2026
Maintained: Buy
Price Target: $34 → $32
Current: $14.27
Upside: +124.25%
Corvus Pharmaceuticals
May 15, 2026
Reiterated: Buy
Price Target: $33
Current: $13.68
Upside: +141.23%
Chemomab Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $25
Current: $1.40
Upside: +1,685.71%
May 15, 2026
Reiterated: Buy
Price Target: $62 → $66
Current: $28.40
Upside: +132.39%
May 13, 2026
Maintained: Buy
Price Target: $6 → $5
Current: $1.33
Upside: +275.94%
May 13, 2026
Reiterated: Buy
Price Target: $50
Current: $33.26
Upside: +50.33%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $5.48
Upside: +82.48%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $3.83
Upside: +82.77%
May 8, 2026
Maintained: Buy
Price Target: $41 → $40
Current: $13.17
Upside: +203.72%
Apr 20, 2026
Maintained: Buy
Price Target: $86
Current: $35.51
Upside: +142.19%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $2.47
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $110.38
Upside: +8.72%
Aug 15, 2025
Maintained: Buy
Price Target: $17 → $16
Current: $5.29
Upside: +202.46%
Aug 14, 2025
Maintained: Buy
Price Target: $19 → $20
Current: $6.38
Upside: +213.48%
Aug 8, 2025
Maintained: Hold
Price Target: n/a
Current: $1.08
Upside: -
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $5.23
Upside: n/a
Aug 14, 2024
Maintained: Hold
Price Target: n/a
Current: $4.92
Upside: n/a
Nov 30, 2023
Maintained: Buy
Price Target: n/a
Current: $2.08
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: n/a
Current: $1.49
Upside: n/a
Nov 7, 2023
Maintained: Buy
Price Target: n/a
Current: $0.8751
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.05
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.011
Upside: n/a
Jun 22, 2021
Maintained: Buy
Price Target: $37
Current: $55.58
Upside: n/a